About Us

We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines.

Our success is rooted in four key elements:

  • Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners
  • Our unique research and development pipeline of new investigational medicines in cancer, pain and immunology
  • Our proprietary and proven science approach that fuels our discovery efforts
  • Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients
  • Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We also have a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.


Latest and Upcoming Investor Events

Contact Nektar Investor Relations

Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs

Jodi Sievers
Director, Investor Relations & Corporate Communications


Transfer Agent and Stockholder Services

Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877) 290-2261
(201) 680-6578